Eugia Pharma's Lenalidomide capsules authorized by the USFDA

26 Jul 2023 , 11:38 AM

According to Aurobindo Pharma, citing IQVIA data, the market size of the approved product is anticipated to be over $210 million for the 12 months ending May 2023. The business announced that the product would be released in July. 

The product is bioequivalent and therapeutically equivalent to the reference listed medicine, Mozobil Injection, 24 mg/1.2 mL (20 mg/mL) of Genzyme Corporation. Eugia Pharma Specialities is a subsidiary of Aurobindo Pharma.

In order to mobilize hematopoietic stem cells to the peripheral circulation for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma (NHL) or multiple myeloma (MM), plerixafor injection is appropriate in combination with granulocyte-colony stimulating factor, according to the statement.

For feedback and suggestions, write to us at [e-mail]